Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

Aggarwal, Rahul, Starzinski, Stephanie, de Kouchkovsky, Ivan · The Lancet Oncology · 2023